Efficacy and safety of a novel oral anti-vasculogenic mimicry agent, CVM-1118, in advanced well-differentiated neuroendocrine tumors: a Phase IIa trial.
First-in-class drug targeting a specific cancer mechanism shows meaningful benefit in rare neuroendocrine tumours with few existing options.
Yen et al. report Phase IIa trial data for CVM-1118, a first-in-class oral agent targeting vasculogenic mimicry in advanced well-differentiated neuroendocrine tumours, demonstrating meaningful objective response and disease control rates at manageable toxicity. Published in British Journal of Cancer, this clinical proof-of-concept supports further evaluation of anti-vasculogenic mimicry as a therapeutic strategy for a cancer type with limited available systemic options.
What the study was
- Study design
- Phase IIa open-label clinical trial
- Population
- Patients with advanced well-differentiated neuroendocrine tumours
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Br J Cancer
Why it surfaced
Phase IIa clinical trial for first-in-class oral anti-vasculogenic mimicry agent in NET; Br J Cancer publication; sentinel signal for novel mechanism in rare cancer with unmet need.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.